Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Biogen Inc. (NASDAQ: BIIB )’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...